Axsome Therapeutics Inc
NASDAQ:AXSM
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
62.55
99.49
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Axsome Therapeutics Inc
Axsome Therapeutics Inc
Cash from Financing Activities
Axsome Therapeutics Inc
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Axsome Therapeutics Inc
NASDAQ:AXSM
|
Cash from Financing Activities
$43.6m
|
CAGR 3-Years
52%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Financing Activities
-$6.4B
|
CAGR 3-Years
27%
|
CAGR 5-Years
21%
|
CAGR 10-Years
5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Financing Activities
$7.7B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Financing Activities
-$5.7B
|
CAGR 3-Years
34%
|
CAGR 5-Years
14%
|
CAGR 10-Years
8%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Financing Activities
-$6.3B
|
CAGR 3-Years
-72%
|
CAGR 5-Years
13%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Financing Activities
$5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Axsome Therapeutics Inc
Glance View
Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. The company is headquartered in New York City, New York and currently employs 108 full-time employees. The company went IPO on 2015-11-19. The firm is engaged in developing therapies for the management of central nervous system (CNS) disorders. The firm's core CNS portfolio includes four CNS product candidates, AXS-05, AXS-07, AXS-12, and AXS-14, which are being developed for multiple indications. AXS-05 is an oral N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity for the treatment of major depressive disorder (MDD). AXS-07 is an oral, rapidly absorbed and multi-mechanistic investigational medicine under development for the acute treatment of migraine. AXS-07 consists of Molecular Solubility Enhanced Inclusion Complex (MoSEIC), meloxicam and rizatriptan. AXS-12, reboxetine, is an oral, investigational medicine in development for the treatment of narcolepsy. AXS-14, esreboxetine, is an oral, investigational medicine in development for the treatment of fibromyalgia.
See Also
What is Axsome Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
43.6m
USD
Based on the financial report for Sep 30, 2024, Axsome Therapeutics Inc's Cash from Financing Activities amounts to 43.6m USD.
What is Axsome Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 5Y
-8%
Over the last year, the Cash from Financing Activities growth was -87%. The average annual Cash from Financing Activities growth rates for Axsome Therapeutics Inc have been 52% over the past three years , -8% over the past five years .
You don't have any saved screeners yet
